146 related articles for article (PubMed ID: 35486292)
21. Prognostic value of pre-transplantation total metabolic tumor volume on
Sugio T; Baba S; Mori Y; Yoshimoto G; Kamesaki K; Takashima S; Urata S; Shima T; Miyawaki K; Kikushige Y; Kunisaki Y; Numata A; Takenaka K; Iawasaki H; Miyamoto T; Ishigami K; Akashi K; Kato K
Int J Hematol; 2022 Oct; 116(4):603-611. PubMed ID: 35701707
[TBL] [Abstract][Full Text] [Related]
22. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
23. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
24. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
25. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effectiveness of
Pichard A; Marcatili S; Karam J; Constanzo J; Ladjohounlou R; Courteau A; Jarlier M; Bonnefoy N; Patzke S; Stenberg V; Coopman P; Cartron G; Navarro-Teulon I; Repetto-Llamazares A; Heyerdahl H; Dahle J; Bardiès M; Pouget JP
Leukemia; 2020 May; 34(5):1315-1328. PubMed ID: 31836849
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
28. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
29. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
[TBL] [Abstract][Full Text] [Related]
30. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
31. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
[TBL] [Abstract][Full Text] [Related]
32. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
33. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
34. Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia.
Nakachi S; Okada M; Morishima S; Agarie Y; Kitamura S; Uchibori S; Tomori S; Hanashiro T; Shimabukuro N; Tamaki K; Tedokon I; Morichika K; Nishi Y; Tomoyose T; Karube K; Fukushima T; Murayama S; Masuzaki H
Hematology; 2017 Oct; 22(9):536-543. PubMed ID: 28397608
[TBL] [Abstract][Full Text] [Related]
35. Nodal metabolic tumour volume on baseline
Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
37. First Extensive Analysis of
Louarn N; Galicier L; Bertinchamp R; Lussato D; Montravers F; Oksenhendler É; Merlet P; Gérard L; Vercellino L
J Clin Oncol; 2022 Apr; 40(12):1346-1355. PubMed ID: 35073166
[TBL] [Abstract][Full Text] [Related]
38. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment.
Fujii H; Tanaka H; Nomoto Y; Harata N; Oota S; Isogai J; Yoshida K
Medicine (Baltimore); 2018 Apr; 97(17):e0543. PubMed ID: 29703034
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
